Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Phillips

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
The Lancet. Haematology|April 2, 2025
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trialJonathan A Cook, Piers E M Patten, Nicholas Peckham, et al.
Blood Advances|April 29, 2026
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC studyToby A Eyre, Nicolás Martínez-Calle, Shankara Paneesha, et al.
Blood Advances|January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Wilson, Wendy Osborne, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Blood Advances|December 21, 2023
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK studyAnn Tivey, Rohan Shotton, Toby A Eyre, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
The Lancet. Haematology|April 2, 2025
A 3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trialJonathan A Cook, Piers E M Patten, Nicholas Peckham, et al.
Blood Advances|April 29, 2026
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC studyToby A Eyre, Nicolás Martínez-Calle, Shankara Paneesha, et al.
Blood Advances|January 12, 2022
Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCLMichael Northend, William Wilson, Wendy Osborne, et al.
The Lancet. Oncology|December 14, 2024
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational studyAnna Santarsieri, Emily Mitchell, My H Pham, et al.
Blood Advances|December 21, 2023
Ibrutinib as first-line therapy for mantle cell lymphoma: a multicenter, real-world UK studyAnn Tivey, Rohan Shotton, Toby A Eyre, et al.
Pageof 6